Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival
Journal of the National Comprehensive Cancer Network · 2023
DOI: 10.6004/jnccn.2022.7098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023. Verfasst von Jake Johnson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Melanoma, Adrenal Insufficiency, Hypophysitis. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Hypophysitis is a serious adverse event stemming from immune checkpoint inhibitor (ICI) therapy for malignancy. This study aimed to characterize ICI-induced hypophysitis, identify diagnostic challenges, and evaluate an association with survival in a large cancer cohort.
Methods
We performed a retrospective cohort study of adult patients with cancer who received ICIs between December 1, 2012, and December 31, 2019. We identified 839 patients who received CTLA-4, PD-1, or PD-L1 inhibitors or a combination thereof who were followed for a median of 19.4 months. Hypophysitis was defined as MRI evidence of pituitary gland and/or stalk enlargement or biochemical evidence of hypopituitarism if not explained by another etiology.
Results
A total of 16 (1.9%) patients developed hypophysitis a median of 7 months after ICI initiation, with most patients having melanoma (9/16; 56.2%) or renal cell carcinoma (4/16; 25%). Two patients also had exogenous glucocorticoid exposure but exhibited secondary hypothyroidism and secondary adrenal insufficiency (AI). Median age at the start of ICI was 61.3 years and 57% were men. Patients who developed hypophysitis were younger compared with those who did not develop hypophysitis (median age, 57 vs 65 years; P =.011). Hypophysitis occurred most frequently after combination therapy (13.7%) compared with CTLA-4 monotherapy (1.9%), PD-1 monotherapy (1.2%), and PD-L1 monotherapy (0.8%) ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
- Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska.
- Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
- VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska.
Zitieren
APA
Johnson, J., Goldner, W., Abdallah, D., Qiu, F., Ganti, A. K., & Kotwal, A. (2023). Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2022.7098
Vancouver
Johnson J, Goldner W, Abdallah D, Qiu F, Ganti AK, Kotwal A. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival. Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2022.7098
BibTeX
@article{Johnson2023,
author = {Johnson, Jake and Goldner, Whitney and Abdallah, Duaa and Qiu, Fang and Ganti, Apar Kishor and Kotwal, Anupam},
title = {Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
doi = {10.6004/jnccn.2022.7098}
}
EUVIMED